US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rapport Therapeutics, Inc.

14.77

-0.1600-1.07%

Post-market: 14.770.00000.00%18:06 EDT

Volume:182.18K

Turnover:2.74M

Market Cap:539.07M

PE:-5.89

High:15.71

Open:15.05

Low:14.73

Close:14.93

52wk High:29.74

52wk Low:6.43

Shares:36.50M

Float Shares:14.96M

Volume Ratio:1.37

T/O Rate:1.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5062

EPS(LYR):-3.7760

ROE:-29.42%

ROA:-20.14%

PB:2.05

PE(LYR):-3.91

Loading ...

Overview Company News Filings

David Bredt, Chief Scientific Officer, Reports Disposal of Common Shares of Rapport Therapeutics Inc

Buy Rating for Rapport Therapeutics Driven by Upcoming Trial Milestone and Strong Pipeline Potential

Rapport Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Rapport (RAPP) Q2 Net Loss Widens 47%

BRIEF-Rapport Therapeutics Reports Second Quarter 2025 Financials And Provides Business Update

Rapport Therapeutics Q2 EPS $(0.75) Beats $(0.85) Estimate

Rapport Therapeutics Inc - Net Loss for Q2 2025 Was $0.75 per Share

THOMSON REUTERS

HC Wainwright Initiates Rapport Therapeutics at Buy With $31 Price Target

MT Newswires Live

Rapport Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview

Citizens JMP Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

David Bredt, Chief Scientific Officer, Reports Disposal of Common Shares of Rapport Therapeutics Inc

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Citizens JMP

Rapport Therapeutics files to sell 470,589 shares of common stock for holders

Rapport Therapeutics Inc. Held Annual Stockholders Meeting

Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc

Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP)

Stifel Nicolaus Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Completes Enrollment for Phase 2a Trial

Rapport Therapeutics Inc. Set to Participate in Jefferies Global Healthcare Conference

Rapport Therapeutics Inc. to Host Inaugural Investor and Analyst Day in New York City

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":14.77,"timestamp":1755892800000,"preClose":14.93,"halted":0,"volume":182177,"hourTrading":{"tag":"盘后","latestPrice":14.77,"preClose":14.77,"latestTime":"18:06 EDT","volume":3186,"amount":47063.65,"timestamp":1755900378390},"delay":0,"floatShares":14959986,"shares":36497920,"eps":-2.506155,"marketStatus":"Market Closed","change":-0.16,"latestTime":"08-22 16:00:00 EDT","open":15.05,"high":15.71,"low":14.73,"amount":2737869.816625,"amplitude":0.06564,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.506155,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756108800000},"marketStatusCode":7,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":14.93,"postHourTrading":{"tag":"盘后","latestPrice":14.77,"preClose":14.77,"latestTime":"18:06 EDT","volume":3186,"amount":47063.65,"timestamp":1755900378390},"volumeRatio":1.37332957613301,"impliedVol":3.1343,"impliedVolPercentile":0.9786},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":14959986,"roa":"-20.14%","roe":"-29.42%","lyrEps":-3.775953,"volumeRatio":1.37332957613301,"shares":36497920,"dividePrice":0,"high":15.71,"amplitude":0.06564,"preClose":14.93,"low":14.73,"week52Low":6.43,"pbRate":"2.05","week52High":29.74,"institutionHeld":0,"latestPrice":14.77,"eps":-2.506155,"divideRate":0,"volume":182177,"delay":0,"ttmEps":-2.506155,"open":15.05,"prevYearClose":17.74,"prevWeekClose":14.705,"prevMonthClose":14.36,"prevQuarterClose":11.37,"fiveDayClose":14.705,"twentyDayClose":16.05,"sixtyDayClose":9.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1754539200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2025-08-22","current":-6.170327,"percent":0.671053,"low":-19.654107,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"high":-3.640031,"avg":-9.35626,"sd":4.204688,"marketCap":544913945},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945}],"updateTime":1755978221452},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2560135759","title":"David Bredt, Chief Scientific Officer, Reports Disposal of Common Shares of Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2560135759","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560135759?lang=en_us&edition=fundamental","pubTime":"2025-08-19 05:14","pubTimestamp":1755551699,"startTime":"0","endTime":"0","summary":"David Bredt, Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL5dxGlJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2559963139","title":"Buy Rating for Rapport Therapeutics Driven by Upcoming Trial Milestone and Strong Pipeline Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2559963139","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559963139?lang=en_us&edition=fundamental","pubTime":"2025-08-14 23:15","pubTimestamp":1755184522,"startTime":"0","endTime":"0","summary":"Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Rapport Therapeutics, Inc.. The associated price target remains the same w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-rapport-therapeutics-driven-by-upcoming-trial-milestone-and-strong-pipeline-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-rapport-therapeutics-driven-by-upcoming-trial-milestone-and-strong-pipeline-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2557559812","title":"Rapport Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2557559812","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557559812?lang=en_us&edition=fundamental","pubTime":"2025-08-08 01:46","pubTimestamp":1754588777,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryRapport Therapeutics Inc RAPP.OQ reported a quarterly adjusted loss of 75 cents per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nL8N3TZ2TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2557561978","title":"Rapport (RAPP) Q2 Net Loss Widens 47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557561978","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557561978?lang=en_us&edition=fundamental","pubTime":"2025-08-07 21:53","pubTimestamp":1754574780,"startTime":"0","endTime":"0","summary":"GAAP net loss increased to $26.7 million in Q2 2025, driven by higher research and development spending and public company costs.The RAP-219 Phase 2a epilepsy trial is fully enrolled and remains on track for topline data in September 2025.Cash reserves totaled $260.4 million as of Q2 2025, projected to fund operations through the end of 2026, with no current revenue streams.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/data-news/2025/08/07/rapport-rapp-q2-net-loss-widens-47/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4135","RAPP","CNS"],"gpt_icon":0},{"id":"2557565527","title":"BRIEF-Rapport Therapeutics Reports Second Quarter 2025 Financials And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557565527","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557565527?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:32","pubTimestamp":1754569934,"startTime":"0","endTime":"0","summary":"BRIEF-Rapport Therapeutics Reports Second Quarter 2025 Financials And Provides Business UpdateAug 7 (Reuters) - Rapport Therapeutics Inc RAPP.O:RAPPORT THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nTUA8YGNZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2557065552","title":"Rapport Therapeutics Q2 EPS $(0.75) Beats $(0.85) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557065552","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557065552?lang=en_us&edition=fundamental","pubTime":"2025-08-07 19:16","pubTimestamp":1754565377,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.85) by 11.45 percent. This is a 55.88 percent increase over losses of $(1.70) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46957788/rapport-therapeutics-q2-eps-0-75-beats-0-85-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","RAPP"],"gpt_icon":0},{"id":"2557552273","title":"Rapport Therapeutics Inc - Net Loss for Q2 2025 Was $0.75 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2557552273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557552273?lang=en_us&edition=fundamental","pubTime":"2025-08-07 19:00","pubTimestamp":1754564403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nTUA8YGNZV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2557008379","title":"HC Wainwright Initiates Rapport Therapeutics at Buy With $31 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2557008379","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557008379?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:45","pubTimestamp":1754480740,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) has an average rating of buy and mean price target of $34.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","RAPP"],"gpt_icon":0},{"id":"2556382854","title":"Rapport Therapeutics Inc  expected to post a loss of 83 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2556382854","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556382854?lang=en_us&edition=fundamental","pubTime":"2025-08-04 21:21","pubTimestamp":1754313666,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc  expected to post a loss of83cents a share - Earnings Preview Rapport Therapeutics Inc RAPP.OQ RAPP.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nL8N3TW15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2552488821","title":"Citizens JMP Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2552488821","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552488821?lang=en_us&edition=fundamental","pubTime":"2025-07-17 17:57","pubTimestamp":1752746272,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason Butler from Citizens JMP reiterated a Buy rating on Rapport Therapeutics, Inc., with a price target of $28.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citizens-jmp-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citizens-jmp-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","JMP"],"gpt_icon":0},{"id":"2552178137","title":"David Bredt, Chief Scientific Officer, Reports Disposal of Common Shares of Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2552178137","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552178137?lang=en_us&edition=fundamental","pubTime":"2025-07-17 04:14","pubTimestamp":1752696882,"startTime":"0","endTime":"0","summary":"David Bredt, the Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL7g9prv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2550620405","title":"Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Citizens JMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2550620405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550620405?lang=en_us&edition=fundamental","pubTime":"2025-07-11 01:25","pubTimestamp":1752168319,"startTime":"0","endTime":"0","summary":"In a report released on July 8, Jason Butler from Citizens JMP reiterated a Buy rating on Rapport Therapeutics, Inc., with a price target of $28.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-receives-a-buy-from-citizens-jmp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-receives-a-buy-from-citizens-jmp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","RAPP","BK4007","BK4127"],"gpt_icon":0},{"id":"2548031410","title":"Rapport Therapeutics files to sell 470,589 shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2548031410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548031410?lang=en_us&edition=fundamental","pubTime":"2025-07-01 19:00","pubTimestamp":1751367614,"startTime":"0","endTime":"0","summary":"06:59 EDT Rapport Therapeutics (RAPP) files to sell 470,589 shares of common stock for holders Published first on TheFly – the ultimate source for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-files-to-sell-470589-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-files-to-sell-470589-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","RAPP","BK4007"],"gpt_icon":0},{"id":"2544188603","title":"Rapport Therapeutics Inc. Held Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2544188603","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544188603?lang=en_us&edition=fundamental","pubTime":"2025-06-19 04:31","pubTimestamp":1750278663,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL4QShRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2544518883","title":"Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2544518883","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544518883?lang=en_us&edition=fundamental","pubTime":"2025-06-19 04:15","pubTimestamp":1750277744,"startTime":"0","endTime":"0","summary":"David Bredt, the Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL4BkWzR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2540087637","title":"Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540087637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540087637?lang=en_us&edition=fundamental","pubTime":"2025-06-03 23:10","pubTimestamp":1748963410,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Tempus AI, Inc. Class A (TEM – Research Report) and Rapport ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-tempus-ai-inc-class-a-tem-and-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-tempus-ai-inc-class-a-tem-and-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4613","BK4141","NA","BK4611","BK4007","BK4121","LU1861558580.USD","LU1861559042.SGD","RAPP","TEM"],"gpt_icon":0},{"id":"2540377569","title":"Stifel Nicolaus Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540377569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540377569?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:47","pubTimestamp":1748947679,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday. The company’s shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","SF"],"gpt_icon":0},{"id":"2540130847","title":"Rapport Therapeutics Completes Enrollment for Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540130847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540130847?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:34","pubTimestamp":1748896471,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has shared an announcement. On June 2, 2025, Rapport Therapeutics announced that its Phase 2a trial for RAP-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-completes-enrollment-for-phase-2a-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-completes-enrollment-for-phase-2a-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2538286468","title":"Rapport Therapeutics Inc. Set to Participate in Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538286468","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538286468?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:00","pubTimestamp":1748343618,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders, will participate in the Jefferies Global Healthcare Conference in New York City. The company's management is scheduled for a fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL1cJ91Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","BK4588","LU2210149790.SGD","BK4112","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","RAPP","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2537823709","title":"Rapport Therapeutics Inc. to Host Inaugural Investor and Analyst Day in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2537823709","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537823709?lang=en_us&edition=fundamental","pubTime":"2025-05-21 19:00","pubTimestamp":1747825234,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company, will host its inaugural Investor and Analyst Day on June 2, 2025, in New York City. The event will focus on the company's clinical programs, highlighting the RAP-219 Phase 2a trial in refractory focal epilepsy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL6yXrnh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","BK4585","LU2210149790.SGD","RAPP","BK4588","BK4007","BK4112","IE00B3QW5Z07.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}